Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;11(1):15-24.
doi: 10.1007/s40487-023-00220-z. Epub 2023 Jan 27.

Patients at the Heart of the Scientific Dialogue: An Industry Perspective

Dany Habr  1 , Brittany Wolf Gianares  2 , Kristine W Schuler  2 , Dheepa Chari  2
Affiliations

Patients at the Heart of the Scientific Dialogue: An Industry Perspective

Dany Habr et al. Oncol Ther. 2023 Mar.

Erratum in

No abstract available

Keywords: Health literacy; Open access; Patient centricity; Plain language summary.

Plain language summary

Pharmaceutical companies need to regularly communicate to patients all essential information about their medicines, especially data from the research studies that were conducted to evaluate the medicine’s benefits and risks. To do that, companies will need to make sure patients have access to and awareness of relevant information. This can be achieved by ensuring medical information is freely available to the reader, and working with publishers to facilitate open access (free) publications. Companies should also help improve patients’ understanding of medical terminology, offer simplified versions of scientific content, and deliver information through various formats (print versus digital, text versus audio versus video) to address different learning styles and literacy levels. This will empower patients with knowledge and improve shared decision-making. It will also be essential for pharmaceutical companies to involve patients in various stages of medicine development, such as getting their input on how the research studies for investigating these medicines are designed and reported to ensure relevant information to patients are well-captured and clear. This should also go in parallel with providing opportunities to elevate the patient voice through patient-partnered research and authorship on topics particularly relevant to them.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient centricity in scientific communications
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yeoman G, Furlong P, Seres M, Binder H, Chung H, Garzya V, et al. Defining patient centricity with patients for patients and caregivers: a collaborative endeavour. BMJ Innov. 2017;3:76–83. doi: 10.1136/bmjinnov-2016-000157. - DOI - PMC - PubMed
    1. Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49:929–939. doi: 10.1177/2168479015580384. - DOI - PMC - PubMed
    1. Perfetto EM, Burke L, Oehrlein EM, Epstein RS. Patient-focused drug development: a new direction for collaboration. Med Care. 2015;53:9–17. doi: 10.1097/MLR.0000000000000273. - DOI - PubMed
    1. Vaida B. Patient-centered outcomes research: early evidence from a burgeoning field. Health Aff (Millwood) 2016;35:595–602. doi: 10.1377/hlthaff.2016.0239. - DOI - PubMed
    1. Furlong P, Bridges JF, Charnas L, Fallon JR, Fischer R, Flanigan KM, et al. How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. Orphanet J Rare Dis. 2015;10:82. doi: 10.1186/s13023-015-0281-2. - DOI - PMC - PubMed

LinkOut - more resources